CS
SLNO

Credit Suisse’s Soleno Therapeutics SLNO Stock Holding History

Credit Suisse’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$737K Buy
17,219
+4,380
+34% +$198K ﹤0.01% 2442
2023
Q4 		$517K Buy
+12,839
New +$365K ﹤0.01% 2709
2021
Q1 		– Sell
-1,236
Closed -$36K – 4531
2020
Q4 		$36K Buy
+1,236
New +$35.7K ﹤0.01% 4275

Other funds holding SLNO

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Credit Suisse's SLNO Position: Q1 2024 in Review

Credit Suisse increased its Soleno Therapeutics (SLNO) stake by 34% in Q1 2024, buying an estimated $198K and bringing the position to 17,219 shares worth $737K. The position accounts for ﹤0.01% of the portfolio, ranked #2442.

Credit Suisse first reported a position in SLNO in Q4 2020 and has held it in 3 quarters since. 98 funds tracked by Wall St. Rank hold SLNO as of Q1 2024.

  • Credit Suisse held 17,219 shares of Soleno Therapeutics worth $737K as of Q1 2024.
  • Credit Suisse bought 4,380 Soleno Therapeutics shares in Q1 2024, an estimated $198K.
  • Soleno Therapeutics made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #2442 holding.
  • Credit Suisse first reported a position in Soleno Therapeutics in Q4 2020 and has held it in 3 quarters since.
  • 98 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.